15th May 2014 07:24
LONDON (Alliance News) - AstraZeneca PLC said Thursday that it will be presenting over 40 scientific abstracts to "demonstrate the rapid progression of its oncology pipeline" at the 50th Annual Meeting of the American Society of Clinical Ongology at the end of May.
It will present data from its Phase I trial for MEDI4736, its Phase I study of AZD9291, and data from a randomised Phase II study investigation a combination of olaparid and cediranib in serous ovarian cancer, amongst others.
AstraZeneca said that its biologics research and development arm MedImmune was building a "comprehensive" immuno-onology programme, with MEDI4736 as one of its leading late stage assets.
Data from the Phase I study of this drug has found encouraging clinical activity and acceptable safety across a range of tumour types so far, AstraZeneca said.
Data from its ongoing Phase I study of AZF9291 for the targeted treatment of lung cancer shows it is well tolerated, and has demonstrated "sustainable anti-cancer activity in lung cancer patients" whose tumours have the EGFR genetic mutation
AstraZeneca has been releasing a flurry of pipeline news over the last week, as it continued to rejected a GBP63 billion approach from US drugsmaker Pfizer Inc. A major defence AstraZeneca has given against a potential takeover is the strength of its growing pipeline, which it says is strong enough to support it as an independent company.
On Monday the company announced a selection of positive data from mid-stage trials from its biological research and development arm MedImmune's respiratory, inflammation and autoimmune portfolio.
On Tuesday, AstraZeneca released positive results from its late-stage study of combination treatment saxagliptin and dapagliflozin for the treatment of type 2 diabetes, which showed that patients treated with the combined drug in addition to metformin, saw a significant reduction in glycated haemoglobin, a key indicator of the control of diabetes.
It also said it would announce Phase IIb data for its asthma treatments benralizumab and tralokinumab at the upcoming American Thoracic Society 2014 International Conference in San Diego on May 16 to 21.
Shares in AstraZeneca are trading up 0.7% at 4,686.50 pence Thursday morning, shortly after the market open.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca